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Background: COPD is associated with increased arterial stiffness which may in part explain the
cardiovascular morbidity observed in the disease. A causal relationship between arterial stiff-
ness and cardiovascular events has not been established, though their strong association raises
the possibility that therapies that reduce arterial stiffness may improve cardiovascular
outcomes. Prior studies suggest that fluticasone propionate/salmeterol (FSC) may improve
cardiovascular outcomes in COPD and we hypothesized that FSC would reduce arterial stiffness
in these patients.
Methods: This multicenter, randomized, double-blind, placebo-controlled study compared the
effects of FSC 250/50 mg twice-daily and placebo on aortic pulse wave velocity (aPWV) as
determined by ECG-gated carotid and femoral artery waveforms. The primary endpoint was
aPWV change from baseline at 12-weeks (last measure for each patient).
Results: 249 patients were randomized; the mean FEV1 in each group was similar (55% pre-
dicted) and 60% of patients reported a cardiovascular disorder. At 12-weeks, aPWV between
FSC and placebo was 0.42 m/s (95%CI 0.88, 0.03; p Z 0.065). A statistically significant
reduction in aPWV between FSC and placebo was observed in those who remained on study5 934 5425; fax: þ1 205 934 6229.
n.com (M.T. Dransfield).
1 Elsevier Ltd. All rights reserved.
FSC and arterial stiffness in COPD 1323drug throughout the treatment period [-0.49 m/s (95%CI 0.98, 0.01; pZ 0.045)]. A post hoc
analysis suggested the effect of FSC was greater in patients with higher baseline aPWV.
Conclusion: FSC does not reduce aPWV in all patients with moderate to severe COPD, but may
have effects in those with elevated arterial stiffness. Additional studies are required to deter-
mine if aPWV could serve as a surrogate for cardiovascular events in COPD.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Although the past decade has witnessed a significant
improvement in the symptomatic treatment of COPD,
mortality in patients with the disease remains high.
Cardiovascular (CV) disease is a major cause of death and
morbidity in COPD and a growing body of epidemiological
evidence demonstrates an association between these
events and impaired lung function that is independent of
smoking.1 The underlying explanation for this phenomenon
remains unclear though possible mechanisms include
endothelial dysfunction, elastin degradation and increased
sympathetic tone that occur in both the systemic vascula-
ture and the emphysematous lung.2e5 These pathologic
processes lead to abnormal vascular function and increased
arterial stiffness. The latter has recently emerged as an
important independent risk factor for CV disease in
a number of population-based studies.6
Aortic pulse wave velocity (aPWV) is the gold standard for
assessing arterial stiffness in research studies and clinical
practice,6 and has been shown to be predictive of CV
outcomes.7 Increased aPWV has been demonstrated in
patients with chronic lung disease including those with COPD
(in whom it correlates with emphysema severity)8 and cystic
fibrosis.9 It was recently demonstrated that there is an
inverse association between both forced expiratory volume
(FEV1) and forced vital capacity (FVC) and aPWV in 800 men
from the Caerphilly Prospective study.10 This finding is sup-
ported by another population-based study demonstrating
a significant association between pulse pressure, a surrogate
for arterial stiffness, and lung function in 13,090 patients
enrolled in the NHANES III study.11
This evidence suggests that increased arterial stiffness
may mediate part of the increased CV risk associated with
impaired lung function.Thoughacausal linkbetweenarterial
stiffness and CV events has not been established, these data
raise the possibility that therapies that decrease arterial
stiffness may improve CV outcomes in COPD. Indeed several
prior reports have suggested that inhaled steroids (ICS) and
the inhaled steroid, long-acting beta agonist combination
fluticasone propionate/salmeterol (FSC) may reduce CV
events and death in patients with COPD12e15 though the
underlying mechanism is unclear. Beta-agonists have been
shown to increase endothelium derived nitric oxide produc-
tion16 and therefore may reduce arterial stiffness in patients
with COPD. Studies in other chronic inflammatory conditions
have demonstrated increased arterial stiffness and endo-
thelial dysfunction and that both can be mitigated with anti-
inflammatory therapy.17,18 Inhaledcorticosteroids are known
to have anti-inflammatory effects and as a result may also
have benefits on arterial stiffness. We hypothesized that FSC
would reduce arterial stiffness compared with placebo in
a group of well characterized COPD patients.Materials and methods
Study design
This was a multicenter, randomized, double-blind, placebo-
controlled study (NCT00857766) conducted in the United
States. In order to qualify for the study, patients could not
be taking ICS or ICS/LABA combination products 30 days
prior to the run-in period. Patients completed a 1e14 day
run-in on short acting beta-agonists followed by a 12-week
double-blind treatment period. Patients were randomized
to fluticasone propionate/salmeterol 250/50 mg twice-daily
via DISKUS (FSC; Advair, Seretide, GlaxoSmithKline,
Research Triangle Park, NC, USA) or placebo DISKUS twice-
daily. After the 12-week treatment period, patients in both
treatment arms received open label tiotropium bromide
Handihaler 18 mg QD (Boehringer Ingelheim GmbH and Co.
KG, Ingelheim, Germany) for 4 weeks in addition to blinded
study drug.
Study patients
The study was approved by each institutional review board
or ethics committee. All patients provided written
informed consent. Patients at least 50 years of age, with
a diagnosis of COPD, and a cigarette smoking history of 10
pack-years were eligible for the study. In addition, patients
were required to have a post-albuterol FEV1 <80% pre-
dicted and a FEV1/FVC ratio 0.70. Patients were excluded
from the study unless classes and dosing of medicines used
for cardiovascular disorders, diabetes, and hyperlipidemia
were stable for 3 months prior to enrollment. If a patient
started medications for cardiovascular disorders, diabetes
or hyperlipidema at anytime during the conduct of the
study they were withdrawn.
Clinical assessments
Aortic PWV (aPWV) was measured at baseline, and weeks 4,
8, 12 and 16 using the SphygmoCorsystem (AtCorMedical,
Sydney, Australia) by sequentially recording ECG-gated
carotid and femoral artery waveforms17 and dividing the
distance between the two recording sites by the wave
transit time. Augmentation Index (AIx) was assessed by
radial artery tonometry using the same device.
Patients underwent a multidetector-row CT scan of the
chest (minimum 16-slice scanner) between randomization
and week 8 for quantitative assessment of emphysema. The
lungs were scanned at full inspiration (120 kVp, 100 mAs,
slice thickness 1 or 1.25-mm for 16-slice scanners and 0.65
or 0.5-mm for 64 slice scanners). The image reconstruction
used a low spatial frequency algorithm (GE e standard,
1324 M.T. Dransfield et al.Siemens e b35f). The extent of emphysema was assessed
quantitatively as the percent low attenuation areas (LAA%)
at 950 HU using the Pulmonary Workstation 2.0 Software
(VIDA Diagnostics, Iowa City Iowa).
Statistical analysis
Wepowered the study to detect a 1.5m/s difference in aPWV
between treatment groups based on previous pilot data.19
Assuming this difference and a standard deviation of 3 m/s,
86 patients per treatment group were needed to achieve 90%
power with a 2-sided significance level of 0.05.19 The primary
efficacymeasure, aPWV change frombaseline at the 12-week
endpoint (defined as the last measurement of aPWV during
the 12-week double-blind treatment period), was compared
between treatment groups using ANCOVA with terms for
treatment group, investigator, sex, smoking status, age, BMI,
waist circumference, and baseline value. Secondary efficacy
analyses of changes in aPWV in those who remained on study
drug throughout the 12-week periods as well as of AIx were
conducted in the same manner. Linear regression modeling
was used to investigate the relationship between aPWV and
study assessments of interest. Univariate analyses were per-
formed with the independent variable aPWV and each
explanatory variable to identify candidate independent
predictors. A stepwise multiple linear regression analysis,
including all explanatory variables (p < 0.10) from theFigure 1 Patient disposition and reasons for withdrawal for the F
groups.univariate analyses, was then performed and covariates with
statistically significant p-values (p < 0.05) were retained.
Statistical programming was performed using SAS.
Results
Of the 370 patients screened, 249 were randomized and
comprised the intent-to-treat population. The details of
patient disposition are shown in Fig. 1 and the baseline
characteristics are shown in Table 1. Patients were
predominantly male and Caucasian though a significant
number of women were enrolled. Approximately half the
patients were active smokers. Sixty percent (60%) of
patients reported having any CV disorder with the highest
prevalence being hypertension (54% in the FSC group; 43%
in the placebo group).
A summary of baseline serum markers of CV risk is
provided in Table 2. There were no differences in these
measures between the placebo and FSC groups.
Baseline data for blood pressure, aPWV, and AIx are
provided in Table 3; no differences between treatment
groups were observed. We found significant univariate
correlations between baseline aPWV and age (r Z 0.26;
p < 0.001), pack-years of smoking (r Z 0.18; p Z 0.006),
systolic (rZ 0.30; p < 0.001) and central systolic (rZ 0.27;
p < 0.001) blood pressure, pulse pressure (r Z 0.30;
p < 0.001), mean arterial pressure (r Z 0.21; p Z 0.001),luticasone propionate/salmeterol 250/50 mg (FSC) and placebo
Table 1 Patient characteristics at baseline.
FSC (N Z 123) Placebo (N Z 126)
Age, yr 63.6  8.9 63.5  7.9
Male, % 55 59
White Caucasian, % 93 90
Current smoker, % 51 47
Pack-years 55.8  27.1 54.1  26.5
BMI, kg/m2 26.7  4.8 26.6  4.2
Waist, cm 95.5  13.7 97.3  11.3
FEV1, L 1.64  0.58 1.65  0.60
FEV1% predicted 56.0  14.9 55.0  15.2
FEV1/FVC ratio 0.54  0.11 0.54  0.11
% Non-reversible 60 59
LAA, %a 8.76  12.24 9.27  10.47
Any CV disease, % 80 (65) 70 (56)
Hypertension, % 67 (54) 54 (43)
Coronary artery disease, % 31 (25) 24 (19)
Peripheral vascular disease, % 6 (5) 7 (6)
Beta-blockers, % 26 (21) 23 (18)
Calcium channel blockers, % 16 (13) 14 (11)
ACE Inhibitors, % 33 (27) 27 (21)
Angiotensin receptor blockers, % 7 (6) 11 (9)
Statins, % 44 (36) 39 (31)
Values are presented as mean  SD or %. FEV1 values are post-bronchodilator. CAD includes past history of myocardial infarction. No
statistically significant differences between groups.
a LAA (%) Z low attenuation area median (IQR) values for FSC Z 4.86 (1.15e11.24) and placebo Z 5.40 (1.74e11.77).
FSC and arterial stiffness in COPD 1325log hsCRP (r Z 0.13; p Z 0.040), log BNP (r Z 0.14;
p Z 0.035), FEV1/FVC ratio (r Z 0.16; p Z 0.014) and
square root CT emphysema (r Z 0.15; p Z 0.046). No
correlation was found between aPWV and FEV1 or BMI. In
multivariate analysis, age, pack-years, and systolic blood
pressure continued to be associated with aPWV.Aortic pulse wave velocity (aPWV)
Data on aPWV at endpoint was available for 113 patients in
the FSC group and 110 patients in the placebo group. The
mean (SE) aPWV for the FSC group decreased from 10.06
(0.26) m/s at baseline to 9.83 (0.24) m/s at endpoint. For
the placebo group the aPWV mean (SE) was 9.87 (0.25) m/s
at baseline and 9.95 (0.26) m/s at endpoint. The least
squares mean difference (SE) between FSC and placebo was
0.42 (0.23) m/s (95%CI 0.88, 0.03; p Z 0.065) (Fig. 2).Table 2 Lab measures at baseline.
FSC (N Z
Cholesterol, mg/dL 185.8 
HDL, mg/dL 56.1 
LDL, mg/dL 102.3 
Triglycerides, mg/dL 139.1 
hsCRP, mg/L 3.3 (1.3e
Fibrinogen, g/L 2.96 (2.4
BNP, ng/L 28 (14e5
Fasting glucose, mg/dL 101.1 
Values for hsCRP, BNP and fibrinogen are median (interquartile rang
patients. No statistically significant differences between groups.These results were unchanged when adjusted for changes in
mean arterial pressure during the study, which were
minimal (0.2 in the FSC group and 0.6 in the placebo
group). We also examined the least squares mean differ-
ence between the study groups in patients who remained
on treatment throughout the 12-week study and found that
FSC (n Z 96) reduced aPWV vs. placebo (n Z 96) 0.49
(0.24) m/s (95% CI 0.98, 0.01; p Z 0.045).Augmentation index (AIx)
Data on AIx at endpoint was available for 114 patients in the
FSC group and 111 patients in the placebo group. No
changes in AIx were observed over the treatment period in
either the FSC group [27.9 (0.83)% at baseline and 27.2
(0.82) % at endpoint] or the placebo group [27.8 (0.83)% at
baseline and 27.6 (0.82)% at endpoint].123) Placebo (N Z 126)
40.9 195.6  44.0
16.6 58.5  22.6
37.2 107.3  39.3




22.0 103.2  23.6
e). All others are mean  SD. All assessments are from fasting
Table 3 Patient hemodynamic measures at baseline.
FSC (N Z 123) Placebo (N Z 126)
Heart rate, beats/min 69.4  11.4 69.9  10.4
SPO2, % 95.7  2.5 95.3  2.3
Systolic pressure, mm Hg 127.8  16.3 127.2  14.6
Diastolic pressure, mm Hg 78.2  9.8 77.9  9.8
Pulse pressure, mm Hg 49.6  13.1 49.3  12.2
Mean arterial pressure, mmHg 94.7  10.7 94.3  10.1
Central systolic pressure, mm Hg 119.1  15.3 117.7  13.6
Central diastolic pressure, mm Hg 79.1  9.9 78.4  9.3
Aortic pulse wave velocity, m/s 10.06  2.85 9.87  2.72
Augmentation index, % 27.9  9.2 27.8  9.2
All values are provided as mean  SD. No statistically significant differences between groups.
Figure 2 aPWV Change from baseline: Values are
means  SE. Filled circles denote the FSC group and the open
circles denote the placebo group. Baseline was defined as the
aPWV measure at visit 2 (randomization) and endpoint was
defined as the last scheduled measurement of aPWV during the
12-week treatment period. Least squares mean difference,
standard error, CI and p-values are from an ANCOVA model with
terms for treatment, investigator, sex, smoking status, age,
BMI, waist circumference, treatment by sex interaction, age by
BMI interaction, and baseline value. Least squares mean
differences are calculated as FSC e Placebo. No statistically
significant difference in aPWV was observed between the FSC
and placebo groups at endpoint (least squares mean difference
(SE) 0.42 (0.23) (95%CI, 0.88, 0.03; p Z 0.065)).
1326 M.T. Dransfield et al.Add on open label tiotropium to the FSC and
placebo group at week 12
No significant changes in aPWV were observed in the
FSC þ tiotropium treatment group (n Z 91) (mean (SE)
change of 0.18 (0.16) m/s) or the placebo þ tiotropium
group (nZ 96) (mean change of 0.18 (0.18) m/s) from week
12 to week 16. The statistically significant treatment
difference between the FSC and placebo groups that was
observed at week 12 was maintained at week 16 (least
squares mean difference (SE) of 0.52 (0.25) m/s) (95%CI
1.01, 0.03; p Z 0.037).
aPWV tertiles at baseline
We also performed a post hoc analysis of the change in
aPWV between study groups in the three tertiles of baseline
aPWV. The ranges of aPWV for tertiles 1, 2 and 3 were 8.7;
>8.7e10.9; and >10.9, respectively. A description of
patient characteristics by tertiles of aPWV at baseline is
provided in Table 4. Patients in tertile 3 were older, more
often former smokers, had greater total pack-years, lower
FEV1/FVC ratio, and greater waist circumference and
mean arterial pressure than those in tertiles 1 and 2. The
least squares mean differences (SE) when comparing FSC
with placebo for tertiles 1, 2 and 3 were 0.19 (0.33);
p Z 0.56; 0.08 (0.48); p Z 0.86; and 1.10 (0.55);
p Z 0.050 (Fig. 3).
Safety
Adverse events (AE) were reported for 58 (47%) patients in
the FSC group and 48 (38%) patients in the placebo group.
Serious adverse events (SAE) were reported for 8 (7%) and 8
(6%) patients in the FSC and placebo groups, respectively.
The SAE reported with the highest incidence in the FSC
group was pneumonia 3 (2%) and worsening of COPD 3 (2%)
in the placebo group.
Discussion
Although many patients with COPD die from respiratory
failure, CV disease is consistently a leading cause of death
depending on the series and the severity of the patients’underlying lung disease.20 Explanations for these observa-
tions have been difficult to elucidate though recent
evidence suggests that the underlying mechanism may be in
part explained by the fact that both CV disease and
emphysema are associated with endothelial dysfunction
and loss of extracellular matrix components like elastin.3,4
These processes in turn lead to abnormal vascular disten-
sibility which can be assessed non-invasively by deter-
mining aPWV. Though a causal link between elevated
Table 4 Description of patient characteristics by tertiles of aPWV at baseline.
Tertile 1 8.7 m/s (N Z 81) Tertile 2 >8.7e10.9 m/s
(N Z 81)
Tertile 3 >10.9 m/s (N Z 78)
aPWV, m/s 7.14  1.24 9.84  0.66 13.02  2.03
Males, % 52 53 64
Age, years 61.4  8.1 61.7  7.0 66.8  8.3a,b
Current smoker, % 58 57 35a,b
Pack-years 51.8  25.2 53.0  22.0 61.4  32.2a,b
FEV1% predicted 56.6  15.2 56.2  14.8 53.7  15.5
FEV1/FVC ratio 0.56  0.11 0.55  0.10 0.51  0.10a
Log hsCRP 0.77  0.87 0.99  1.00 1.09  1.12a
Log BNP 3.02  1.01 3.12  0.87 3.34  0.91a
Any CVD, % 52 70 55b,c
LAA(%) 950 HU 7.2  9.4 9.8  14.3 10.1  10.5
BMI, kg/m2 26.1  4.3 26.6  5.0 27.1  4.3
Waist, cm 94.3  12.6 96.2  13.6 98.8  11.3a
Systolic BP, mmHg 122.0  16.0 128.0  14.2 132.0  14.9a,c
Diastolic BP, mmHg 76.9  10.9 78.0  9.5 78.7  8.8
Pulse pressure, mmHg 45.1  12.6 50.0  12.2 53.3  11.8a,c
MAP, mmHg 91.9  11.4 94.7  9.7 96.5  9.7a
Data are presented as the mean  SD unless otherwise indicated. P-values are from chi-square tests for categorical variables and from
one-way ANOVA for continuous variables. aPWVZ aortic pulse wave velocity. Log hsCRPZ the log of high sensitivity c-reactive protein.
Log BNP Z log of B-type natriuretic peptide. CVD Z cardiovascular disease. LAA (%) Z low attenuation area%. MAP Z mean arterial
pressure.
a p < 0.05 Tertile 1 vs. Tertile 3.
b p < 0.05 Tertile 2 vs. Tertile 3.
c p < 0.05 Tertile 1 vs. Tertile 2.
Figure 3 Change aPWV from baseline in the FSC group.
Values are means  SE. Open circles denote Tertile 1. Open
triangles denote Tertile 2. Open squares denote Tertile 3.
Tertile 1 was defined by having baseline aPWV measures
8.7 m/s; Tertile 2 was defined as having baseline aPWV >8.7
and 10.9 m/s and Tertile 3 was defined as having baseline
aPWV >10.9 m/s. The least squares mean difference (SE)
between FSC and placebo was 0.19 (0.33), p Z 0.56 for
Tertile 1, 0.08 (0.48), pZ 0.86 for Tertile 2, and 1.10 (0.55),
p Z 0.050 for Tertile 3.
FSC and arterial stiffness in COPD 1327arterial stiffness and CV events has not been definitively
established, their association raises the possibility that
treatments that reduce aPWV may in turn improve cardio-
vascular outcomes. Proof that aPWV may serve as a surro-
gate for CV events in COPD is beyond the scope of the
current trial which was designed to determine if FSC exerts
biologically relevant effects on arterial stiffness. In this
study FSC treatment did not meet the a priori reduction in
aPWV defined as clinically meaningful in the intention-to-
treat population. However, compared with placebo FSC
reduced aPWV in those who remained on study drug
throughout the treatment period and this effect was more
pronounced in those with greater baseline arterial stiff-
ness. This is the first large scale efficacy trial to examine
the impact of inhaled therapy on arterial stiffness in COPD
and suggests that FSC may reduce aPWV. If confirmed in
larger studies, and when combined with outcomes data
linking reductions in aPWV to improvements in CV
morbidity, these results may help explain prior observations
suggesting that FSC reduces CV events in COPD.12,13
The high prevalence of CV disease and death in COPD
patients may result from traditional risk factors including
cigarette smoking as well as recently recognized shared risks
including systemic inflammation.21 Several studies have
suggested that arterial stiffness, as assessed by PWV, is
elevated in patients with COPD and that this is independent
of cigarette smoking and perhaps FEV1.
4,8,22e24 It has been
argued that this results from an inflammatory process that
occurs in both the vasculature and emphysematous lung
leading to endothelial dysfunction and elastin degradation.
Indeed, Coulson et al. have shown that COPD patients with
elevated aPWV have increased aortic inflammation as
1328 M.T. Dransfield et al.assessed by 18F-FDG PET scanning as compared with healthy
ex-smokers.25 Sabit et al.8 have also reported a correlation
between serum IL-6 and aPWV r (rZ 0.31, p < 0.01) though
McAllister et al.4 found no relationship between PWV and
serum CRP. In that study, a correlation was observed
between PWV and the severity of CT emphysema (rZ 0.47,
p < 0.001) perhaps implicating a shared inflammatory
process. In the current study we found univariate correla-
tions between aPWV and both CT emphysema and hsCRP
though these were not significant on multivariate testing.
These data suggest that increased arterial stiffness in COPD
may result from abnormalities in the vascular extracellular
matrix and that this may be a systemic feature of the disease
leading to increased CV risk.
Several prior studies have shown that both beta-agonists
and corticosteroids can reduce arterial stiffness.18,24 The
effects of beta-agonists may be mediated via systemic
stimulation of endothelial nitric oxide synthase while
corticosteroids may reduce systemic inflammation which is
known to contribute to atherosclerosis.21 The impact of
inhaled corticosteroids (ICS) and ICS/long-acting beta
agonist combinations on markers of systemic inflammation
has been debated. Though Sin et al. have shown that as
compared with placebo, fluticasone propionate reduced
serum CRP in patients with COPD26 a subsequent trial of FSC
demonstrated no such effect.27 In a post hoc analysis of the
TORCH study Calverley et al.12 also found that after
adjustment for drug exposure the probability of having a CV
adverse event was lowest in patients taking FSC (20.8%) as
compared with those taking fluticasone propionate or sal-
meterol alone and statistically lower than in patients taking
placebo (24.2%; p Z 0.031). Similarly, in a two year trial
comparing FSC and tiotropium in patients with severe
COPD, a lower rate of death due to CV events was observed
in those in the FSC group (1% vs. 3%, p > 0.05).13 Though our
trial was not powered to directly compare the effects of
tiotropium and FSC on arterial stiffness, the difference in
aPWV observed at week 12 was maintained between FSC-
tiotropium and placebo-tiotropium in the open label
phase of the study.
Two prior studies have specifically examined the impact
of active treatments on arterial stiffness in COPD. Viv-
odtzev et al. have shown that PWV was reduced after 4
weeks of exercise in ten trained COPD patients (10.3 m/
se9.2 m/s; p Z 0.001) as compared with seven untrained
patients matched for age and lung function.28 Though these
data support the possibility that arterial stiffness can be
modulated in COPD, the study was limited by its non-
randomized design, the use of carotid-radial rather than
the gold standard carotid-femoral PWV and the fact that
the authors did not account for the reduction in systolic
blood pressure that occurred with exercise. Blood pressure,
both central and peripheral, is a major determinant of PWV
and the 8 mm Hg reduction observed in the trained patients
could explain the observed arterial stiffness improvements.
Blood pressure improvements during the current study were
minimal and the results were not altered in analyses
adjusting for these changes. In the second small trial, Sabit
et al. evaluated the effects of FSC in 14 patients with
moderate-severe COPD and observed that treatment
significantly reduced arterial stiffness at 8 weeks by 2.2 m/
s (p < 0.01).19 This study provided the only preliminary dataregarding the impact of FSC on aPWV in COPD and led us to
select our estimated effect size of 1.5 m/s and to power
the trial. There are several differences between the design
of this prior trial and the current report that may explain
why we were unable to demonstrate a statistically signifi-
cant reduction in aPWV in our intention-to-treat population
(p Z 0.065). First, Sabit et al. utilized the 500/50 dose of
FSC as compared with the 250/50 dose used in our study.
Second, patients in the Sabit trial had more severe airflow
limitation (mean FEV1 1.01 L vs. 1.65 L) and this may in part
explain why they also had significantly higher resting aPWV
(13 m/s vs. 10 m/s). This may have limited our power to
detect an effect of active treatment on aPWV. Indeed,
though limited by the post hoc analysis, a statistically
significant reduction in arterial stiffness was observed in
those in the highest tertile of baseline aPWV (>10.9 m/s).
Though the change in aPWV with FSC was less than
expected, Orlova et al. have reported that in patients with
coronary artery disease any decrease in PWV over 6 months
was associated with a four-fold reduction in the risk of
major cardiac events over 3.5 years of follow-up. The
association observed in this observational study cannot be
used to determine the clinical relevance of the change in
aPWV we observed. However this study can also not be used
to exclude the possibility that a small reduction in aPWV
may be meaningful.29
There are several limitations to our study. First, as we
did not include study arms with the individual FSC compo-
nents we were unable to determine the relative effects of
each drug on aPWV. The use of ICS alone in COPD is
currently not recommended however, and thus the relevant
limitation is the lack of a salmeterol arm. Despite this, the
published observational data suggest that the greatest
benefits on CV outcomes are achieved with FSC as
compared with either drug alone. Second, we did not find
any reduction in AIx with FSC in either the intent-to-treat
or post hoc analyses. This is of interest as AIx is correlated
with long term CV outcomes though the relationship is not
as robust as that for aPWV.2,6,7 In addition, AIx is a complex
parameter affected by arterial stiffness, systemic vascular
resistance, and left ventricular function and thus may be
less sensitive for the detection of the effects of FSC. This
may be particularly relevant in our study population as AIx
tends to plateau beginning at age 50 while aPWV continues
to increase.30 Third, though the tertile analysis suggested
that FSC reduced arterial stiffness in patients with the
highest baseline aPWV, it is also possible that the effect we
observed in this subgroup was not the result of study drug
but due to the regression of their elevated aPWV towards
the mean. This is somewhat unlikely given that there was
no reduction in aPWV in placebo treated patients in this
subgroup. Fourth, it is also possible that a longer treatment
period might be required to demonstrate a statistically
significant reduction in aPWV. Lastly, though patients were
excluded from the trial if they began or had been recently
prescribed new medications that may impact aPWV, the
overall use of proven cardioprotective drugs (e.g. beta-
blockers, statins, angiotensin converting enzyme inhibi-
tors) was relatively low despite the 60% prevalence of CV
disease.
The mechanism by which FSC may lower aPWV remains
unknown. Though beta-agonists and corticosteroids have
FSC and arterial stiffness in COPD 1329both been shown to reduce arterial stiffness16,18 the
systemic bioavailability of salmeterol and fluticasone
propionate when delivered by inhalation is very low31 and
argues against a direct pharmacologic effect. As discussed,
it has been postulated that ICS may reduce systemic
inflammation indirectly by downregulating airway derived
IL-6 which in turn reduces CRP expression by the liver26
though not all reports support this hypothesis.27 It has
also been shown that patients with COPD have elevated
sympathetic activation even in the absence of hypoxemia
and that this may be driven by dyspnea or abnormal lung
hyperinflation.32 As sympathetic output has been directly
linked to aPWV,5 it is possible that aPWV is reduced in COPD
in response to the beneficial effects of FSC on lung hyper-
inflation and resulting improvements in shortness of breath
and respiratory mechanics. As has been noted recently,
emphysema and hyperinflation can have important
extrapulmonary effects including those on cardiac perfor-
mance.33,34 Additional studies would be required to better
examine this possibility.
In summary, this is the first large scale trial to accurately
examine the effect of inhaled anti-inflammatory and
bronchodilator therapy on aPWV in a well characterized
COPD population. Although the study did not meet the
primary endpoint, it does suggest FSC may reduce aPWV in
patients with the greatest abnormality in arterial stiffness
and provides preliminary data for future trials examining
the impact of COPD therapies on aPWV. When combined
with large outcome studies establishing a link between
reductions in aPWV and subsequent CV events, these
studies will allow a better understanding of the potential
CV impact of COPD treatments.Conflict of interest
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